Corporate | 10 December 2009 07:45
4SC AG / Miscellaneous
10.12.2009
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
4SC AG Receives Research Grant from the Bavarian Research Foundation
Planegg-Martinsried, Germany, 10 December, 2009 - 4SC AG (Frankfurt, Prime
Standard: VSC), a drug discovery and development company, today announced
that it has received, as part of a consortium, a research grant from the
Bavarian Research Foundation (Bayerische Forschungsstiftung) to fund the
discovery of protein kinase inhibitors as potential therapies for the
treatment of herpes viruses.
The consortium composed of 4SC, Kinaxo Biotechnologies AG, Martinsried,
Germany, and the Virological Institute of the Erlangen University Hospital,
Germany, will receive EUR 700,000 for this three year project. The
research project will focus on the discovery of small-molecule kinase
inhibitors with a dual-mode of action that can selectively inhibit viral
and cellular protein kinases. Kinase inhibitors are a commonly used drug
class in cancer and inflammation as they can modulate signalling pathways
in cells which can lead to various disease states. In viral diseases,
current molecular treatments inhibit either a viral target or a target in
the infected host cell. However, this approach allows viruses to build
resistance quickly, as they are able to mutate and continue to replicate in
host cells. By investigating protein kinase inhibitors in viral diseases,
it is hoped that a dual-mode of action could target the virus and host
cells concurrently, thereby potentially delaying a resistance to treatments
for longer.
Dr Daniel Vitt, Chief Scientific Officer at 4SC AG, commented, 'We are
pleased to have received this research grant in order to support our drug
discovery. At 4SC, research is an integral part of our business strategy
as it ensures the future generation of clinical drug candidates for our
pipeline. Working closely with research institutions and companies is an
important part of this process as it helps us to remain at the forefront of
new research and drive the innovation required to develop more effective
medicines for patients in the future.'
Ends -
About 4SC
4SC AG (ISIN DE0005753818) is a drug discovery and development company
focused on autoimmune and cancer indications. The company currently has
three clinical programs, with three further clinical trials planned to
commence in 2009. 4SC-101, a small molecule, is in a Phase IIb study in
rheumatoid arthritis as well as in a Phase IIa exploratory study in
inflammatory bowel disease. The company's lead oncology compound, 4SC-201,
a histone deacetylase (HDAC) inhibitor, is in a Phase II trial in
hepatocellular carcinoma and is due to commence a further Phase II trial in
Hodgkin's lymphoma in 2009. Drug candidates are developed until
proof-of-concept in order to generate value creating partnerships with the
pharmaceutical industry in return for advance and milestone payments as
well as royalties.
4SC was founded in 1997, has 93 employees, and is listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.
For further information please visit www.4sc.com.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
For more information please contact
4SC AG
Yvonne Alexander, IR & PR
Tel.: +49 (0) 89 70 07 63 66
MC Services (Europe)
Stefan Riedel
Tel.: +49 (0) 89 21 02 28 40
The Trout Group (USA)
Chad Rubin
Tel.: +1 646 378 2947
10.12.2009 Financial News distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------